1. Home
  2. APA vs MDGL Comparison

APA vs MDGL Comparison

Compare APA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo APA Corporation

APA

APA Corporation

HOLD

Current Price

$32.99

Market Cap

12.9B

Sector

Energy

ML Signal

HOLD

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$503.93

Market Cap

11.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APA
MDGL
Founded
1954
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9B
11.1B
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
APA
MDGL
Price
$32.99
$503.93
Analyst Decision
Hold
Strong Buy
Analyst Count
23
12
Target Price
$31.96
$674.45
AVG Volume (30 Days)
4.7M
245.0K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
2.48%
N/A
EPS Growth
75.77
41.32
EPS
1.26
N/A
Revenue
N/A
$180,133,000.00
Revenue This Year
$3.86
$58.39
Revenue Next Year
N/A
$48.55
P/E Ratio
$26.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.87
$279.33
52 Week High
$45.66
$615.00

Technical Indicators

Market Signals
Indicator
APA
MDGL
Relative Strength Index (RSI) 33.86 52.28
Support Level $22.73 $498.59
Resistance Level $38.75 $502.97
Average True Range (ATR) 1.17 19.92
MACD -0.46 2.65
Stochastic Oscillator 6.19 86.62

Price Performance

Historical Comparison
APA
MDGL

About APA APA Corporation

APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: